Curable compositions and membranes

Patent metadata

Field	Value
Publication number	US-9527973-B2
Application number	US-201314391728-A
Country	US
Kind code	B2
Filing date	Mar 22, 2013
Priority date	Apr 12, 2012
Publication date	Dec 27, 2016
Grant date	Dec 27, 2016

Abstract

A process for preparing a membrane comprising applying a curable composition to a porous support and curing the composition, wherein the composition comprises: a) a curable ionic compound; b) a first crosslinking agent; c) a second crosslinking agent; d) an inert solvent; and e) optionally a free radical initiator; wherein the second crosslinking agent has a melting point below 80° C. Also claimed are the compositions and membranes obtainable by using the process.

First claim

The invention claimed is:

1. A process for preparing a membrane comprising applying a curable composition to a porous support and curing the curable composition, wherein the curable composition comprises:
a) a curable ionic compound;
b) a first crosslinking agent comprising at least two acrylate groups or at least two acrylamide groups;
c) a second crosslinking agent comprising at least two acrylic groups;
d) an inert solvent; and
e) optionally a free radical initiator;

wherein (i) the melting point of the first crosslinking agent is 80° C., below 80° C., or above 80° C.; (ii) the second crosslinking agent has a melting point below 80° C.; (iii) the second crosslinking agent is not the same as the first crosslinking agent; (iv) the curable composition comprises 3 to 35 wt % of the first crosslinking agent and 2 to 25 wt % of the second crosslinking agent; and (v) the total amount of crosslinking agents is at least 17 wt %; wherein the amounts are based on the total weight of the curable composition.

2. The process according to claim 1 wherein the first crosslinking agent comprises at least two acrylamide groups.

3. The process according to claim 1 wherein the curable ionic compound comprises an acrylamide group.

4. The process according to claim 1 wherein the curable ionic compound comprises an ionic group selected from quaternary ammonium, sulpho, phosphato and carboxy.

5. The process according to claim 1 wherein the curable composition comprises less than 25 wt % of component d).

6. The process according to claim 1 wherein the curable composition further comprises f) a non-curable salt.

7. The process according to claim 6 wherein the non-curable salt is selected from lithium chloride, lithium bromide, lithium nitrate, lithium iodide, lithium chlorate, lithium thiocyanate, lithium hydroxide, ammonium thiocyanate, ammonium chloride, ammonium iodide, ammonium nitrate, sodium chloride, sodium bromide, sodium nitrate, sodium thiocyanate, calcium nitrate, calcium thiocyanate, calcium bromide, magnesium chloride, magnesium bromide, magnesium nitrate, magnesium thiocyanate, potassium thiocyanate, potassium chlorate, and mixtures comprising two or more such salts.

8. The process according to claim 1 wherein the inert solvent comprises less than 30 wt % inert organic solvent and the remaining inert solvent is water.

9. The process according to claim 1 wherein the curable composition comprises:
1) 20 to 80 wt % of curable ionic compound(s);
2) 17 to 60 wt % of crosslinking agents; and
3) 5 to 45 wt % of inert solvent(s).

10. The process according to claim 1 wherein:
(i) the first crosslinking agent comprises at least two acrylamide groups;
(ii) the curable composition comprises less than 25 wt % of component d)
(iii) optionally the curable composition further comprises an inorganic salt; and
(iv) optionally the inert solvent comprises less than 30 wt % inert organic solvent and any remaining inert solvent is water.

11. The process according to claim 1 wherein the curable composition is cured using ultraviolet light.

12. The process according to claim 1 wherein:
(i) the first crosslinking agent comprises at least two acrylamide groups;
(ii) the curable ionic compound comprises an acrylamide group; and
(iii) the curable composition comprises less than 25 wt % of component d).

13. The process according to claim 1 wherein the curable composition comprises 5 to 25 wt % of the first crosslinking agent and 3 to 20 wt % of the second crosslinking agent.

14. The process according to claim 1 wherein the curable composition comprises:
i) 20 to 80 wt % of the curable ionic compound;
ii) 5 to 45 wt % of the inert solvent;
iii) 0 to 10 wt % of the free radical initiator; and
iv) 0 to 50 wt % of a non-curable salt.

15. A membrane obtained by the process according to claim 1 .

16. The membrane obtained by the process according to claim 10 .

17. A membrane obtained by the process according to claim 14 .

18. An electrodialysis or reverse electrodialysis unit, an electrodeionization module, a continuous electrodeionization module, a flow through capacitor, a fuel cell, a diffusion dialysis apparatus, a membrane distillation module or a membrane electrode assembly, comprising one or more membranes according to claim 15 .

19. An electrodialysis or reverse electrodialysis unit, an electrodeionization module, a continuous electrodeionization module, a flow through capacitor, a fuel cell, a diffusion dialysis apparatus, a membrane distillation module or a membrane electrode assembly, comprising one or more membranes according to claim 16 .

Assignees

• Fujifilm Mfg Europe Bv

Inventors

• Hessing Jacko
• Van Baak Willem

Classifications

• C02F1/4695

  electrodeionisation · CPC title

• C08J5/2231 Primary

  based on macromolecular compounds obtained by reactions involving unsaturated carbon-to-carbon bonds · CPC title

• B01D61/48

  having one or more compartments filled with ion-exchange material {, e.g. electrodeionisation} · CPC title

• B01D69/02

  characterised by their properties · CPC title

• B01D61/44

  Ion-selective electrodialysis · CPC title